Meetings and manufacturing supplements are estimated to rise in FY 2022, while one less biosimilar application is expected, compared to the current fiscal year. • Source: Alamy
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
